Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Status:
Completed
Trial end date:
2017-02-17
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus
placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Aevi Genomic Medicine Aevi Genomic Medicine, LLC, a Cerecor company